IRVINE, Calif.--(BUSINESS WIRE)--Onset Medical Corporation announced today that the Food and Drug Administration (“FDA”) has granted clearance to begin marketing the Company’s SoloPathTM transseptal access catheter in the United States. SoloPath utilizes Onset’s patented Controlled Deployment Technology (“CDT”) to allow percutaneous access to the chambers of the left heart and surrounding vasculature.
